C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research
TUCSON, Ariz.,
DMD is a rare, fatal, X-linked, muscle wasting, and progressive disease that predominantly affects boys but has been shown to manifest in some female carriers. Research and development in this area have been challenging due to the complexities associated with the disease.
Developed by C-Path's Quantitative Medicine Program and D-RSC, together with an extensive group of collaborators, this simulator utilizes advanced models of the longitudinal changes in the velocity at which individuals can complete specified, timed functional tests. These tests, which include the supine-stand, 4-stair climb, 10-meter walk/run test, or 30-foot walk/run test, are frequently used as clinical trial endpoints. Additionally, the tool models longitudinal changes in forced vital capacity and the North Star Ambulatory Assessment total score, providing a comprehensive approach to trial design for simulation. A key feature of the DMD Clinical Trial Simulator is its incorporation of relevant sources of variability such as baseline severity at study start, age, steroid use, genetic mutation and study type. This ensures that the simulations are as realistic and informative as possible, paving the way for more effective and efficient clinical trial designs.
In
"The launch of the DMD Clinical Trial Simulator represents a significant step forward in our fight against Duchenne muscular dystrophy," said
"The DMD Clinical Trial Simulator is poised to become a valuable resource for researchers and pharmaceutical companies involved in DMD research," commented C-Path CEO
The CTS will be made publicly available on c-path.org, here, and hosted on the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), C-Path's designated analytics hub for data analysis and generation of drug development tools across multiple rare diseases.
"We advance the RDCA-DAP platform as a place for innovation for rare disease drug development and are excited to offer open access to C-Path's drug development tools on RDCA-DAP. Granting access to the D-RSC Clinical Trial Simulator through RDCA-DAP creates a unique opportunity for innovative trial designs in DMD," said Alexandre Bétourné, Pharm.D., Ph.D., Executive Director, RDCA-DAP.
About D-RSC:
D-RSC (Duchenne Regulatory Science Consortium) is comprised of a team of experts dedicated to advancing the understanding and treatment of Duchenne muscular dystrophy through innovative research and technology solutions.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA's Critical Path Initiative. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is in
Contacts:
C-Path
520.954.1634
[email protected]
C-Path
615.310.1894
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/c-path-launches-clinical-trial-simulator-for-duchenne-muscular-dystrophy-research-302102815.html
SOURCE Critical Path Institute
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- COMMERCIAL OBSERVER TO HOST HIGHLY ANTICIPATED STATE OF OFFICE FORUM AT VORNADO REALTY TRUST'S PENN 2 AS DATA SUGGESTS RECOVERY IS UNDERWAY & POINTS TO INCREASE IN DEMAND FOR TROPHY ASSETS
- IntraCare Marks Major Milestone: Significant Partnership Finalized with Arizona's Multi-Clinic Cornerstone Family Medicine
- Collectors and eBay Transactions Close, Summer Launch Expected for Integrated, End-to-End Hobby Experience
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!